During CML trial NCT01725204, dasatinib (100 mg pd) was combined with pegylated interferon-α2b (peg IFN) at three months (M3) at an initial dose of 15 μg/week, later increasing to 25 μg/week from M6 to M15. This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.